Regarding the role of FENO in predicting failure after ICS reduction in mild-to-moderate asthma patients

Luis Pérez de Llano, Nagore Blanco Cid, Irene Martin Robles, Rafael Golpe, Olalla Castro-Añon, David Dacal Rivas

Source: Eur Respir J, 56 (2) 2002375; 10.1183/13993003.02375-2020
Journal Issue: August
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Luis Pérez de Llano, Nagore Blanco Cid, Irene Martin Robles, Rafael Golpe, Olalla Castro-Añon, David Dacal Rivas. Regarding the role of FENO in predicting failure after ICS reduction in mild-to-moderate asthma patients. Eur Respir J, 56 (2) 2002375; 10.1183/13993003.02375-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005

FENO as a biomarker guide for inhaled corticosteroid step down in patients with mild-to-moderate well-controlled asthma
Source: Eur Respir J, 55 (5) 2001319; 10.1183/13993003.01319-2020
Year: 2020



Does an acute FEV1 response predict long-term improvements with bronchodilators in patients with COPD?
Source: Eur Respir J 2001; 18: Suppl. 33, 486s
Year: 2001

Assessing bronchodilator response in patients with asthma and COPD using 19F-MRI
Source: Virtual Congress 2020 – New imaging techniques applied to old problems
Year: 2020


Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma.
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020


Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020


Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
Source: ERJ Open Res, 6 (1) 00204-2019; 10.1183/23120541.00204-2019
Year: 2020



Evaluation of the individual bronchodilator response in patients with severe COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 246s
Year: 2002

Smoking, sputum cell counts, diffusion capacity and hyperinflation predict beneficial effects of long-term inhaled corticosteroids (ICS) on FEV1-decline in patients with mild-to-moderate COPD
Source: Annual Congress 2010 - COPD: management
Year: 2010

Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007


The effect of high dose bronchodilators on cardiac function in elderly people with severe COPD or asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 407s
Year: 2002

How frequent is bronchodilator reversibility in patients with stable asthma bronchiale and chronic obstructive lung disease (COPD) receiving maintenance therapy?
Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use
Year: 2012


Short-term effects of pulmonary rehabilitation on asthma control in patients with moderate-severe unstable asthma
Source: International Congress 2019 – Hot topics in pulmonary rehabilitation
Year: 2019

Inhaled corticosteroids decrease exercise-induced inflammation in patients with COPD
Source: Annual Congress 2007 - Mechanisms of exercise intolerance in cardiorespiratory disease
Year: 2007


Catabolic/anabolic balance in patients with COPD exacerbation
Source: Eur Respir J 2004; 24: Suppl. 48, 305s
Year: 2004

QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013

Mild improvement in symptoms and pulmonary function in a long-term follow-up of patients with TDI-induced asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 604s
Year: 2005

Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility
Source: Eur Respir J 2002; 20: Suppl. 38, 243s
Year: 2002

Ceruloplasmine efficacy in patients with asthma exacerbations
Source: Annual Congress 2011 - Novel mechanisms in lung injury
Year: 2011